LUNG DATA REVIEW 2025
May 1, 2025



MARIPOSA: Head-to-head study demonstrated amivantamab + lazertinib benefits patients with previously untreated EGFR-mutant advanced NSCLC compared to single agent osimertinib and should be considered as a standard of care in the front line setting as a non-chemotherapy regimen

COCOON: Enhanced dermatologic management (COCOON DM) reduced dermatologic side effects compared to standard care in EGFR-mutant non-small cell lung cancer patients treated with amivantamab plus lazertinib, allowing more patients to remain on treatment

SKIPPirr: Incorporating prophylactic dexamethasone (8 mg, 5 doses) into treatment with amivantamab plus lazertinib can effectively prevent and reduce infusion related reactions

PALOMA-3 and -2: Incorporating prophylactic anticoagulation into treatment with amivantamab and lazertinib reduced venous thromboembolic events (VTEs)
More to come from **COPERNICUS**

TROPION-Lung05 / 01 Pooled Analysis: Dato-DXd has the potential to provide an additional treatment option for patients with previously treated EGFR-mutated NSCLC on tumor progression
Yet to be approved…
VENTANA TROP2 RxDx Device received breakthrough designation April 29, 2025

WU-KONG1: Sunvozertinib as a single oral drug has the potential to benefit patients with NSCLC and an EGFR exon20ins mutation who progressed on or after platinum-based chemotherapy
More to come…

eXALT3: The second-generation ALK inhibitor ensartinib represents an additional first-line treatment option for ALK-positive NSCLC patients…now FDA approved
Multiple options available…Optimal sequencing to be determined

eNRGy: Zenocutuzumab provides a treatment option for patients with NRG1+ NSCLC
Now FDA approved making it the first drug that targets tumors with the very rare NRG1 fusion genetic alteration

VISION: With long-term follow-up, tepotinib provides clinically meaningful benefit for patients with mNSCLC with METexon14 alterations, especially if treatment naïve

KRYSTAL-7: First-line adagrasib plus pembrolizumab has potential as a treatment option for patients with KRASG12C-mutated NSCLC and PD-L1 ≥50% (KEYNOTE-024: 1L pembro alone, PFS 10.3 months). More to come…ongoing phase III trials…

BEAMION Lung-1: Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) Not yet approved…PDUFA date is third quarter of 2025

KROCUS: Fulzerasib plus cetuximab provides benefit with an impressive objective response rate of 80% for patients with previously untreated advanced KRAS G12C mNSCLC and was superior to SoC established by the KEYNOTE-189 trial, which compared pemetrexed and platinum-based chemotherapy with or without pembrolizumab (Keytruda)…More to come…

LUNAR: Optune Lua is a portable medical device that could potentially offer a nontoxic supplemental treatment option for patients with metastatic NSCLC who have progressed on or after a platinum-based regimen

DeLLphi-300 / -301: Tarlatamab benefits patients with previously treated SCLC and could be considered a standard of care in the appropriate patient
Signal of intracranial activity…more to come
Monitoring and management of treatment related toxicities is key

ATLANTIS: Combination therapy with lurbinectedin plus doxorubicin did not improve overall survival versus control in patients with relapsed SCLC

LUPER: Small study of lurbinectedin plus pembrolizumab in patients with relapsed SCLC
More to come…

IMforte: Rress release suggests statistically significant overall survival and progression-free survival results for combination of lurbinectedin and atezolizumab in first line maintenance therapy for ES-SCLC
More to come…

ADRIATIC: Now FDA approved…
Durvalumab consolidation therapy should be considered a new standard of care option for patients with LS-SCLC regardless of prior exposure to prophylactic cranial irradiation (PCI) or concurrent chemoradiotherapy (CRT) components

Program Chairs

TAREK MEKHAIL, MD
Medical Director Thoracic Cancer Program
AdventHealth Medical Group, Orlando, FL

SUJITH R. KALMADI, MD
Chief Medical Officer
Ironwood Cancer and Research Centers, Phoenix, AZ

ERIC S. SCHAEFER, MD
Highlands Oncology Group, Fayetteville, AR

cornerstone specialty network™

© 2025 Cornerstone Specialty Network, LLC.
All rights reserved.

P.O. Box 173 - New Hope, PA 18938
5/2025